Q4 2025 Rhythm Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Rhythm Pharmaceuticals Inc (RYTM) reported strong revenue growth for the fourth quarter and full year 2025, with a 50% increase in full-year revenue compared to 2024.
- The company is well-capitalized, ending 2025 with approximately $389 million in cash, cash equivalents, and short-term investments, expected to fund operations for at least 24 months.
- The Phase 2 study of bivamelagon showed promising results with significant BMI reductions, and the FDA has confirmed readiness to move to Phase 3.
- Rhythm Pharmaceuticals Inc (RYTM) has expanded its sales force significantly in preparation for the potential launch of IMCIVREE for acquired hypothalamic obesity, indicating strong commercial readiness.
- The company has made significant international progress, with IMCIVREE now available in more than 25 countries outside the United States, including eight new countries added in 2025.
- The FDA requires a full 12-month double-blind randomized control trial for bivamelagon, which may delay the timeline for approval.
- There are compliance issues with younger patients in the bivamelagon trial, particularly related to the size of the pills.
- The company anticipates a potential dampening effect on first-quarter sales due to inventory build-up at the end of 2025.
- Research and development expenses remain high, with $42 million reported for the fourth quarter of 2025.
- The company reported a net loss per basic and diluted share of $0.73 for the fourth quarter of 2025, indicating ongoing financial challenges.
Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals fourth quarter and fiscal year 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Dave Connolly. Please go ahead.
Thank you, Tanya. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the investor section of our website, IR.rhythmtx.com. This morning we issued a press release that provides the fourth quarter 2025 and full year 2025 financial results and a business update, and that press release is also available on our website.
Our agenda is listed on slide 2. On the call today are David Meeker, our Chairman, Chief Executive Officer and President; Jennifer Lee, Executive Vice President, Head of North America; Hunter Smith,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
